Larger clinical trials are needed to assess whether Roche’s Actemra (tocilizumab) can cut death rates among the sickest Covid-19 patients after a small study found the arthritis drug was no better than standard care in severe cases.

Researchers called for more research into using blood from recovered Covid-19 patients – or so-called convalescent plasma – as a potential treatment, after a small trial of hospitalized patients in India found it was of no benefit.

Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.